原发性肝癌TACE前后血清uPA含量变化及其意义

The change and its clinical significance of uPA levels in patients with HCC before and after TACE

目的探讨uPA在原发性肝癌介入治疗前后的表达变化及其临床意义。方法采用ELISA方法测定50例原发性肝癌患者经皮肝动脉插管化疗栓塞术(TACE)术前3天、术后3天、7天、2周及4周血清uPA的含量及100例健康体检者血清uPA水平。结果实验组血清中uPA的含量明显高于对照组(P<0.01);肝癌患者血清uPA含量在门脉癌栓组、已发生转移组、肿瘤多发组中显著增高(P<0.01、P<0.01、P<0.05),而在不同肿瘤大小、肝功分级和AFP含量组之间无明显统计学差异(P>0.05);与TACE术前3天比较,实验组术后3天、术后7天、术后2周血清中uPA的含量明显下降(P<0.05),术后4周血清中uPA含量与术前3天比较无明显统计学差异(P>0.05)。结论uPA含量的高低与肝癌的侵袭性高低有关。TACE前后血清uPA的检测有助于更好的掌握再次TACE治疗的时机。

Objective To investigate the change and its clinical significance of urokinase type plasminogen activator （uPA） levels in patients with primary hepatocellular carcinoma （HCC） before and after the interventional therapy .Methods The uPA levels in 50 patients with HCC were detected by ELISA 3 days before transcatheterarterial chemoembolization （TACE）, as well as 3 days, 7 days, 2 weeks and 4 weeks after TACE. The uPA levels in 100 healthy people were detected by ELISA only once. Result The level of uPA in patients with HCC before TACE was higher than those in control group （P〈0.01）.The level of uPA was higher in portal vein carcinoma throumbs, metastasis and multiple tumors group （P〈0.01, P〈0.01, P〈0.05） but similar in different tumor size, liver function and AFP group （P〉0.05）.Compared with that of 3 days before TACE, the level of uPA declined remarkably （P〈0.05） 3 days, 7 days, 2 weeks and 4 weeks after TACE; however no significant change of uPA level was detected 4 weeks after TACE （P〉0.05）. Conclusion uPA levels mainly relate to the invasion of tumor. Detecting uPA levels before and after TACE might be helpful for seizing the opportune moment to adopt TACE again.